# EDGAR Filing Document

**Accession Number:** 0002023311
**File Stem:** 0001213900-26-060585
**Filing Date:** 2026-5
**Character Count:** 16002
**Document Hash:** e18661c65b00eb78a29947511af99caf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-060585.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001213900-26-060585

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260520

**FILED AS OF DATE**: 20260522

**DATE AS OF CHANGE**: 20260522

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Yang Dajun
- **CENTRAL INDEX KEY:** 0002059751

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42484
- **FILM NUMBER:** 261014101

**MAIL ADDRESS:**
- **STREET 1:** C/O ASCENTAGE PHARMA GROUP INC.
- **STREET 2:** 700 KING FARM BLVD., SUITE 510
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASCENTAGE PHARMA GROUP INTERNATIONAL
- **CENTRAL INDEX KEY:** 0002023311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **PROVINCE COUNTRY:** F4
- **BUSINESS PHONE:** 86 512 8555 7777

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **PROVINCE COUNTRY:** F4

## Ex-24

```
<pre>
      POWER OF ATTORNEY

The undersigned hereby makes, constitutes and appoints each of Thomas J. Knapp
and Leslie Brault, or either of them acting singly, and with full power of
substitution, re-substitution and delegation, the undersigned's true and lawful
attorney in fact (each of such persons and their substitutes and delegees being
referred to herein as the "Attorney-in-Fact"), with full power to act for the
undersigned and in the undersigned's name, place and stead, in the undersigned's
capacity as an officer, director or stockholder of Ascentage Pharma Group
International (the "Company"), to:
1.	Take such actions as may be necessary or appropriate to enable the
undersigned to submit and file forms, schedules and other documents with the
U.S. Securities and Exchange Commission ("SEC") utilizing the SEC's Electronic
Data Gathering and Retrieval ("EDGAR") system, which actions may include (a)
enrolling the undersigned in EDGAR Next and (b) preparing, executing and
submitting to the SEC a Form ID, amendments thereto, and such other documents
and information as may be necessary or appropriate to obtain codes and passwords
enabling the undersigned to make filings and submissions utilizing the EDGAR
system;
2.	Prepare and execute any and all forms, schedules and other documents
(including any amendments thereto) the undersigned is required to file with the
SEC, or which the Attorney-in-Fact considers it advisable for the undersigned to
file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act
of 1934 or any rule or regulation thereunder, or under Rule 144 under the
Securities Act of 1933 ("Rule 144"), including Forms 3, 4 and 5, Schedules 13D
and 13G, and Forms 144 (all such forms, schedules and other documents being
referred to herein as "SEC Filings");
3.	Submit and file SEC Filings with the SEC utilizing the EDGAR system or cause
them to be submitted and filed by a person appointed under Section 5 below;
4.	File, submit or otherwise deliver SEC Filings to any securities exchange on
which the Company's securities may be listed or traded;
5.	Act as an account administrator for the undersigned's EDGAR account,
including: (i) appoint, remove and replace account administrators, account
users, technical administrators and delegated entities; (ii) maintain the
security of the undersigned's EDGAR account, including modification of access
codes; (iii) maintain, modify and certify the accuracy of information on the
undersigned's EDGAR account dashboard; (iv) act as the EDGAR point of contact
with respect to the undersigned's EDGAR account; and (v) any other actions
contemplated by Rule 10 of Regulation S-T with respect to account
administrators;
6.	Cause the Company to accept a delegation of authority from any of the
undersigned's EDGAR account administrators and, pursuant to that delegation,
authorize the Company's EDGAR account administrators to appoint, remove or
replace users for the undersigned's EDGAR account; and
7.	Obtain, as the undersigned's representative and on the undersigned's behalf,
information regarding transactions in the Company's equity securities from any
third party, including the Company and any brokers, dealers, employee benefit
plan administrators and trustees, and the undersigned hereby authorizes any such
third party to release any such information to the Attorney-in-Fact.
The undersigned acknowledges that:
a.	This Power of Attorney authorizes, but does not require, the Attorney-in-Fact
to act in his or her discretion on information provided to such Attorney-in-Fact
without independent verification of such information;
b.	Any documents prepared or executed by the Attorney-in-Fact on behalf of the
undersigned pursuant to this Power of Attorney will be in such form and will
contain such information as the Attorney-in-Fact, in his or her discretion,
deems necessary or desirable;
c.	Neither the Company nor the Attorney-in-Fact assumes any liability for the
undersigned's responsibility to comply with the requirements of Section 13 or
Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for
any failure to comply with such requirements, or any liability of the
undersigned for disgorgement of profits under Section 16(b) of the Exchange Act;
and
d.	This Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under Section 13 or Section 16
of the Exchange Act, including, without limitation, the reporting requirements
under Section 13 or Section 16 of the Exchange Act.
The undersigned hereby grants to the Attorney-in-Fact full power and authority
to do and perform each and every act and thing requisite, necessary or advisable
to be done in connection with the foregoing, as fully, to all intents and
purposes, as the undersigned might or could do in person, hereby ratifying and
confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Power of
Attorney.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigned's holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all
previous powers of attorney with respect to the subject matter of this Power of
Attorney.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
February 10, 2026.

Dajun Yang

State of Indiana
County of Warrick

This Power of Attorney was acknowledged before me on February 10, 2026 by Dajun
Yang.

/S/Kaitlyn Conner
Notary Signature

[Notary Seal]
    </pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Yang Dajun<br><sub>(Last) (First) (Middle)</sub><br>C/O ASCENTAGE PHARMA GROUP INC.<br>700 KING FARM BLVD., SUITE 510<br><sub>(Street)</sub><br>ROCKVILLE, MD 20850<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chairman and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2026-05-21 |  | M |  | 95575 | A | $0 | 1193569 | D |  |
| Ordinary Shares | 2026-05-21 |  | M |  | 92746 | A | $0 | 405280 | I | See Footnote <sup>(2)(2)</sup> |
| Ordinary Shares |  |  |  |  |  |  |  | 22054131 | I | See Footnote <sup>(1)(1)</sup> |
| Ordinary Shares |  |  |  |  |  |  |  | 14089111 | I | See Footnote <sup>(3)(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted stock units<sup>(4)</sup> | $0 | 2026-05-20 |  | A |  | 95575 |  | 2026-05-21 | <sup>(4)</sup> | Ordinary Shares | 95575 | $0 | 95575<sup>(4)</sup> | D |  |
| Restricted stock units<sup>(5)</sup> | $0 | 2026-05-21 |  | M |  |  | 95575<sup>(5)</sup> | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 95575 | $0 | 0 | D |  |
| Restricted stock units<sup>(6)</sup> | $0 | 2026-05-20 |  | A |  | 298195 |  | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares | 298195 | $0 | 0 | D |  |
| Options<sup>(7)</sup> | $6.58 | 2026-05-20 |  | A |  | 298194 |  | <sup>(7)</sup> | <sup>(7)</sup> | Ordinary Shares | 298194 | $0 | 298194 | D |  |
| Restricted stock units<sup>(8)</sup> | $0 | 2026-05-20 |  | A |  | 103365 |  | <sup>(8)</sup> | <sup>(8)</sup> | Ordinary Shares | 103365 | $0 | 103365 | I | By Spouse |
| Restricted stock units<sup>(6)</sup> | $0 | 2026-05-20 |  | A |  | 214999 |  | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares | 214999 | $0 | 214999 | I | By Spouse |
| Options<sup>(7)</sup> | $6.58 | 2026-05-20 |  | A |  | 214988 |  | <sup>(7)</sup> | <sup>(7)</sup> | Ordinary Shares | 214988 | $0 | 214988 | I | By Spouse |
| Options<sup>(9)</sup> | $8.12 | 2026-05-20 |  | A |  | 103364 |  | <sup>(9)</sup> | <sup>(9)</sup> | Ordinary Shares | 103364 | $0 | 103364 | I | By Spouse |
| Restricted stock units<sup>(10)</sup> | $0 | 2026-05-20 |  | A |  | 92746 |  | 2026-05-21 | <sup>(10)</sup> | Ordinary Shares | 92746 | $0 | 92746 | I | By Spouse |
| Restricted stock units<sup>(11)</sup> | $0 | 2026-05-21 |  | M |  |  | 92746 | <sup>(11)</sup> | <sup>(11)</sup> | Ordinary Shares | 92746 | $0 | 0 | I | By Spouse |

---

### Footnotes:

(1) Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

(2) Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

(3) Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

(4) Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date.

(5) Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026.

(6) The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date.

(7) The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant.

(8) The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date.

(9) The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant.

(10) The RSUs vested on 05/21/2026 and had no expiration date.

(11) Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026.

**Signature:** /S/Thomas J. Knapp, as attorney-in-fact  
**Date:** 2026-05-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**